Search published articles


Showing 4 results for Inflammatory Bowel Disease
Clinical and epidemiological characteristics in ulcerative colitis patients referred to Imam Hospital, 1995-2000
Ebrahimi Daeiani N, Mohammadi Hr, Airamloo M,
Volume 59, Issue 4 (8-2001)
Abstract
Inflammatory bowel diseases are one of the important reasons of the referral to GI practitioners in our country and Ulcerative Colitis is the more frequent type of these disease in Iran. In this study 200 cases of Ulcerative Colitis, which has been referred to Imam Khomeini Hospital during that last 5 year, were studied. Data was collected using the patient's records and face to face interview with them and their relatives. Majority of the patients were female (55 percent). Positive family history was seen in 28 percent of patients, autoimmune disease history in 8 percent, smoking history in 11 percent and smoking cessation history in 13 percent of patients. Most prevalent symptoms in the patients were nocturnal bleeding, rectal bleeding and bloody diarrhea. The most common involved area were recto sigmoid (58 percent) and descending colon (42 percent). Pan colitis was seen in 8 percent. Most people had complications and the most common complications was fissure (14 percent). Recurrence was seen in 83.5 percent of patients. With logistic regression analysis the only variable which showed significant relation with recurrence was male sex. According to the results of this study, it seems that ulcerative colitis clinical and epidemiological pattern in Iran is similar to many other countries, but the higher rate of recurrence and extra intestinal manifestations in patients shows that there is a growing need to reconsider the treatment efficacy in patients and correct the treatment methods.
Evaluation of the relationship between serum vitamin D levels and disease recurrence in patients with ulcerative colitis
Ahmad Hormati, Majid Azad, Abolfazl Mohammadbeigi , Vajihe Maghsoudi, Sajjad Rezvan, Mohammad Hossein Mokhtarian, Mahboubeh Afifian,
Volume 79, Issue 6 (9-2021)
Abstract
Background: one of the growing diseases in the world that affects patient life quality is Inflammatory bowel disease (IBD), including ulcerative colitis (UC). Many environmental factors, including nutritional deficiencies, may influence the development of the disease. This study aims to evaluate the role of the level of vitamin D in UC recurrence.
Methods: We performed this cross-sectional study at Qom University of Medical Sciences from September 2017 to September 2018 on 50 patients with inactive UC, at least six months after diagnosis, in Shahid Beheshti Hospital in Qom. Patients entered the study sequentially from the target population after describing how to perform the plan and obtaining informed consent. Demographic information, including gender, age, medical history, diseases, and body mass index (BMI), were collected using a checklist. Patients were followed for six months for symptoms and the frequency of disease relapse. During the visits, in terms of adherence to treatment and case of recurrence, the number and severity of recurrence were examined, and the results were recorded in the checklist of each patient. At the end of this period, serum vitamin D level was measured. Data were collected by a checklist and analyzed by independent samples t-test, Chi-square, and variance analysis in SPSS version 18.
Results: Examining the correlation between vitamin D levels and demographic variables shows that low vitamin D levels are significantly associated with an increase in the frequency of recurrences. However, there was no significant relationship between disease duration, age, and body mass index. Among 50 patients, 23 (%46) were male, and 27 (%54) were female, with a mean age of 35.24±10.07 and a mean duration of disease for 15.14±6.67 months. The mean frequency of relapse was 1.34±1.89. The mean level of serum vitamin D was 22.30±13.45 ng/dl. It was significantly associated with the frequency of relapse with a P<0.001.
Conclusion: Vitamin D insufficiency is associated with an increased risk of recurrence in patients with ulcerative colitis.
 

Concurrence of familial mediterranean fever and inflammatory bowel disease in a seven-year-old girl with henoch-schönlein purpura: a case report
Niloofar Shashaani, Vadood Javadi Parvaneh, Reza Shiari , Khosro Rahmani,
Volume 83, Issue 1 (4-2025)
Abstract
Background: Immunoglobulin A (IgA) vasculitis or Henoch–Schönlein Purpura (HSP) is a systemic vasculitis of small vessels associated with IgA deposition. It is the most common Vasculitis in childhood and presents with a wide spectrum of clinical manifestations, most commonly palpable purpura, renal involvement, and arthritis. However, its manifestations are not limited to these organs and may also involve other systems of the body. The coexistence of Henoch–Schönlein purpura with other autoimmune and autoinflammatory diseases has been reported. In particular, its association with Familial Mediterranean Fever (FMF), Inflammatory Bowel Disease (IBD), and Behcet Disease (BD) has been observed in different studies. Patients with Familial Mediterranean Fever who develop Henoch–Schönlein purpura usually exhibit more severe and prolonged inflammatory symptoms. Therefore, reporting the co-occurrence of these diseases can provide a better understanding of the spectrum of clinical manifestations and diagnostic-therapeutic challenges.
Case Presentation: This case describes a 7-year-old girl with initial manifestations of Henoch–Schönlein purpura, who, due to severe gastrointestinal symptoms, underwent further evaluations. In the performed investigations, the coexistence of Familial Mediterranean Fever and Inflammatory Bowel Disease was diagnosed, and incomplete Behcet Disease was also considered. The patient was placed under appropriate medical treatment. Finally, the patient was controlled with appropriate medical treatment.
Conclusion: This report shows that in children with Henoch–Schönlein purpura, especially in severe and recurrent cases, the possibility of associated autoimmune and autoinflammatory diseases such as Familial Mediterranean Fever, Inflammatory Bowel Disease, and Behcet Disease should be considered. These associated diseases can play a key role in the course of appropriate treatment.

The beneficial effects of Lactobacillus brevis in inflammatory bowel disease, clinical effects and therapeutic prospects: a review article
Ardeshir Ebrahiminejad Shahroudi, Abbas Akhavan Sepahi , Anna Meyfour, Abbas Yadegar, Sedigheh Mehrabian,
Volume 83, Issue 7 (10-2025)
Abstract
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal disorder characterized by persistent inflammation of the intestinal mucosa, disruption of epithelial barrier function, and dysregulation of the immune system. Its pathogenesis involves complex interactions among genetic predisposition, environmental factors, gut microbiota, and host immune responses. Dysregulated cytokine signaling plays a central role, with elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, IL-12, and interferon-gamma (IFN-γ), contributing to tissue damage, epithelial barrier dysfunction, and clinical manifestations such as diarrhea, bleeding, and weight loss. Conversely, anti-inflammatory cytokines, including interleukin-10 (IL-10), IL-35, and IL-37, counteract these inflammatory responses, inhibit excessive immune activation, and maintain mucosal homeostasis. Probiotics, particularly Lactobacillus strains, have emerged as promising adjunctive therapies for IBD due to their capacity to restore microbial balance, modulate immune responses, and enhance gut barrier integrity. Among them, Lactobacillus brevis has demonstrated significant immunoregulatory and anti-inflammatory effects. Various strains, including AL0035, SBC8803, Bmb6, HY7401, and KU15152, reduce pro-inflammatory cytokines, upregulate tight junction proteins such as ZO-1, regulate Th1/Th2/Th17 responses, and inhibit NF-κB and MAPK signaling pathways. L. brevis-derived metabolites, notably long-chain polyphosphates, attenuate fibrosis, reduce TGF-β1 and collagen expression, and protect epithelial cells from oxidative stress. Heat-killed L. brevis strains also retain immunomodulatory activity, allowing therapeutic use even when live bacteria cannot effectively colonize the gut. Preclinical studies demonstrate that oral administration of L. brevis improves disease activity indices in experimental colitis models, reduces mucosal immune cell infiltration, restores epithelial integrity, and prevents ulceration, bleeding, and goblet cell depletion. Clinical evidence, although limited, suggests that L. brevis supplementation can enhance gut microbiota diversity, increase beneficial bacterial populations, and modulate serum cytokines, further supporting intestinal homeostasis. Furthermore, L. brevis influences metabolite profiles, such as serotonin and polyamines, which are linked to gut motility, epithelial repair, and immune regulation, highlighting its multifaceted role in gut health. In this review article, for the first time, we discussed the beneficial effects of L. brevis in inflammatory bowel disease, highlighting its clinical effects and therapeutic prospects.
 

Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb